Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies

Maroof Hasan, Nan Yan

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

The serine/threonine protein kinase, TBK1, plays a crucial role as the hub for many innate immune signaling pathways that lead to the induction of type I interferon (IFN) and interferon-stimulated genes (ISGs). Due to its key function in maintaining homeostasis of the immune system, cell survival and proliferation, TBK1 activity is tightly regulated. Dysregulation of TBK1 activity is often associated with autoimmune diseases and cancer, implicating the potential therapeutic benefit for targeting TBK1. Tremendous effort from both academic institutions and private sectors during the past few years has led to the development of many potent and selective TBK1 inhibitors, many of which have shown great promise in disease models in vivo. This review summarizes recent advance on the pharmacological inhibition of TBK1 and its potential for treating autoimmune diseases and interferonopathies.

Original languageEnglish (US)
Pages (from-to)336-342
Number of pages7
JournalPharmacological Research
Volume111
DOIs
StatePublished - Sep 1 2016

Fingerprint

Autoimmune Diseases
Interferon Type I
Private Sector
Protein-Serine-Threonine Kinases
Interferons
Immune System
Cell Survival
Homeostasis
Cell Proliferation
Pharmacology
Therapeutics
Genes
Neoplasms

Keywords

  • Autoimmune disease
  • Interferonopathy
  • Lupus
  • TBK1
  • Type I interferon

ASJC Scopus subject areas

  • Pharmacology

Cite this

Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies. / Hasan, Maroof; Yan, Nan.

In: Pharmacological Research, Vol. 111, 01.09.2016, p. 336-342.

Research output: Contribution to journalReview article

@article{fa12203da1fc4863a777cfa42e280895,
title = "Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies",
abstract = "The serine/threonine protein kinase, TBK1, plays a crucial role as the hub for many innate immune signaling pathways that lead to the induction of type I interferon (IFN) and interferon-stimulated genes (ISGs). Due to its key function in maintaining homeostasis of the immune system, cell survival and proliferation, TBK1 activity is tightly regulated. Dysregulation of TBK1 activity is often associated with autoimmune diseases and cancer, implicating the potential therapeutic benefit for targeting TBK1. Tremendous effort from both academic institutions and private sectors during the past few years has led to the development of many potent and selective TBK1 inhibitors, many of which have shown great promise in disease models in vivo. This review summarizes recent advance on the pharmacological inhibition of TBK1 and its potential for treating autoimmune diseases and interferonopathies.",
keywords = "Autoimmune disease, Interferonopathy, Lupus, TBK1, Type I interferon",
author = "Maroof Hasan and Nan Yan",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.phrs.2016.04.008",
language = "English (US)",
volume = "111",
pages = "336--342",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies

AU - Hasan, Maroof

AU - Yan, Nan

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The serine/threonine protein kinase, TBK1, plays a crucial role as the hub for many innate immune signaling pathways that lead to the induction of type I interferon (IFN) and interferon-stimulated genes (ISGs). Due to its key function in maintaining homeostasis of the immune system, cell survival and proliferation, TBK1 activity is tightly regulated. Dysregulation of TBK1 activity is often associated with autoimmune diseases and cancer, implicating the potential therapeutic benefit for targeting TBK1. Tremendous effort from both academic institutions and private sectors during the past few years has led to the development of many potent and selective TBK1 inhibitors, many of which have shown great promise in disease models in vivo. This review summarizes recent advance on the pharmacological inhibition of TBK1 and its potential for treating autoimmune diseases and interferonopathies.

AB - The serine/threonine protein kinase, TBK1, plays a crucial role as the hub for many innate immune signaling pathways that lead to the induction of type I interferon (IFN) and interferon-stimulated genes (ISGs). Due to its key function in maintaining homeostasis of the immune system, cell survival and proliferation, TBK1 activity is tightly regulated. Dysregulation of TBK1 activity is often associated with autoimmune diseases and cancer, implicating the potential therapeutic benefit for targeting TBK1. Tremendous effort from both academic institutions and private sectors during the past few years has led to the development of many potent and selective TBK1 inhibitors, many of which have shown great promise in disease models in vivo. This review summarizes recent advance on the pharmacological inhibition of TBK1 and its potential for treating autoimmune diseases and interferonopathies.

KW - Autoimmune disease

KW - Interferonopathy

KW - Lupus

KW - TBK1

KW - Type I interferon

UR - http://www.scopus.com/inward/record.url?scp=84979084979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979084979&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2016.04.008

DO - 10.1016/j.phrs.2016.04.008

M3 - Review article

C2 - 27353409

AN - SCOPUS:84979084979

VL - 111

SP - 336

EP - 342

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -